# Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

> **NCT03684863** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 200 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03684863
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03684863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03684863, "Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03684863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*